On October 16, 2023 Starpharma (ASX: SPL, OTCQX: SPHRY) reported a copy of the DEP irinotecan combination data poster, showcasing the recently announced data for DEP irinotecan in combination with leading anticancer therapies, including immuno-oncology (IO) agents, in human colorectal cancer (CRC) models (Press release, Starpharma, OCT 16, 2023, View Source;mc_eid=bf52dd3418 [SID1234635974]). The data show that DEP irinotecan in combination with an IO agent or a PARP2 inhibitor demonstrated superior anti-tumour activity and significant survival benefit when compared to these agents delivered alone in multiple CRC models.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster was presented over the weekend in Boston, US, at the international oncology conference, AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper), co-hosted by the American Association of Cancer Research (AACR) (Free AACR Whitepaper), the National Cancer Institute (NCI) and the European Organisation for Research and Treatment of Cancer (EORTC) from 11 to 15 October 2023.

This promising combination data, together with the recently released positive clinical results for DEP irinotecan, provide a strong rationale for clinical evaluation of DEP irinotecan with these leading classes of cancer drugs. These combinations are commercially important because they increase the potential market opportunities for DEP irinotecan and illustrate valuable synergies with successful product categories.